phrykt

Rani Therapeutics Holdings, Inc. (RANI): who owns it and who trades it

As of Nov 16, 2026, RANI insiders reported 1 open-market sale worth $301 and 2 purchases worth $50K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Alireza Javadi (Chief Technical Officer), with $301. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Rani Therapeutics Holdings

From the latest filings

Overall: more buying than selling. Insiders and famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns RANI

66 funds and institutions reported RANI shares worth $34.6M at the end of Q2 2026. The largest holder is Samsara Biocapital, LLC with $7.9M.

10 largest owners, by value

Samsara Biocapital, LLC$7.9M
Ra Capital Management, L.P.$6.5M
AWM Investment Company, Inc.$5.7M
Vanguard Capital Management LLC$3.5M
Longaeva Partners L.P.$1.8M
Polar Asset Management Partners Inc.$1.8M
Siren, L.L.C.$1.5M
Heights Capital Management, Inc$711K
Geode Capital Management, LLC$678K
Citadel Advisors LLC$488K

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Samsara Biocapital, LLC10.37M–$7.9M+22%
Ra Capital Management, L.P.8.50M–$6.5MNo change
AWM Investment Company, Inc.7.50M–$5.7M+15%
Vanguard Capital Management LLC4.56M–$3.5M-1%
Longaeva Partners L.P.2.33M–$1.8MNo change
Polar Asset Management Partners Inc.2.32M–$1.8MNew
Siren, L.L.C.2.00M–$1.5MNo change
Heights Capital Management, Inc934,580–$711KNew
Geode Capital Management, LLC890,618–$678K-1%
Citadel Advisors LLC641,995–$488KNew
Marshall Wace, LLP586,265–$446KNew
Nan Fung Group Holdings Ltd493,584–$375KNo change
Jane Street Group, LLC485,899–$369K+193%
Vanguard Fiduciary Trust Co458,126–$348K+1%
Renaissance Technologies LLC430,737–$328KNew
State Street Corp373,142–$284KNo change
BlackRock, Inc.342,113–$260K-39%
United Services Automobile Association302,743–$230KNo change
UBS Group AG297,270–$226K+31%
Kestra Private Wealth Services, LLC282,340–$215K+6%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, RANI insiders reported $50K of open-market purchases and $301 of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$50K
2 trades, 2 people
Sales, 12 months
$301
1 trades, 1 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Jul 21, 2026
Filed Jul 23, 2026

Purchases and sales by month

$50K$50KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jul 21, 2026Mir A ImranDirectorPurchase36,000$0.69$24.8KForm 4
Jul 17, 2026Talat ImranCEOPurchase35,000$0.72$25.2KForm 4
Mar 27, 2026Alireza JavadiChief Technical OfficerSale386$0.78$301Form 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Talat ImranChief Executive Officer, Director$25.2K–Jul 17, 2026
Mir A ImranDirector, 10% owner$24.8K–Jul 21, 2026
Alireza JavadiChief Technical Officer–$301Mar 27, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

RANI short interest

8.22M RANI shares are sold short. Over the last 12 reports the number of shares short went up 3%.

As of Oct 30, 2026, 8.22M RANI shares were sold short, up 0.8% from the report before. At the average daily volume of 477,910 shares, buying them all back would take about 17.2 trading days (days to cover).

Shares short

8.22MMay 15Oct 309.48M

Days to cover

17.2May 15Oct 3019.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20268.22M–+1%477,91017.2
Oct 15, 20268.16M–+13%574,31014.2
Sep 30, 20267.25M–+2%624,09411.6
Sep 15, 20267.12M–+11%475,65715.0
Aug 31, 20266.39M–-22%788,8378.1
Aug 14, 20268.16M–-4%577,21014.1
Jul 31, 20268.46M–-4%1.22M6.9
Jul 15, 20268.85M–-3%783,52811.3
Jun 30, 20269.08M–+17%524,60617.3
Jun 15, 20267.77M–+5%922,1408.4
May 29, 20267.38M–-7%1.29M5.7
May 15, 20267.96M–-11%942,7498.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Rani Therapeutics Holdings company events

Rani Therapeutics Holdings filed 9 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership, listing). The latest was on Nov 9, 2026.

  1. Nov 9, 2026ResultsReleased financial results. Filing
  2. Aug 13, 2026ResultsReleased financial results. Filing
  3. Aug 4, 2026LeadershipMichelle Gilson was appointed to the Board, effective immediately, until the earlier of the Company’s next annual meeting of stockholders, the appointment and qualification of her successor, or her death, resignation, or removal. Filing
  4. Jun 30, 2026LeadershipRani Therapeutics Holdings, Inc. announced the appointment of Nicholas M. Maestas as the Company’s Chief Financial Officer (principal financial officer and principal accounting officer) effective as of June 29, 2026. Filing
  5. May 29, 2026VoteReported shareholder vote results. Filing
  6. May 27, 2026AnnouncementRani Therapeutics Holdings, Inc. entered into a securities purchase agreement with certain institutional investors, relating to the issuance and sale, of 12,476,637 shares of our Class A common stock, par value $0.0001 per share, and pre-funded warrants to purchase 6,214,953 shares of Class A… Filing
  7. May 15, 2026ListingThe Company received a letter from the Nasdaq Stock Exchange LLC, notifying the Company that, based on the closing bid price of the Company’s Class A common stock, par value $0.0001 per share, for the prior 30 consecutive business days, the Company no longer complies with the minimum bid price… Filing
  8. Mar 26, 2026ResultsReleased financial results. Filing
  9. Jan 2, 2026AgreementEnded an important agreement. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Rani Therapeutics Holdings financials

Famous investors that hold RANI

3 of the 50 well-known investors we track reported holding RANI in their latest 13F filing. The largest position is Israel Englander's, worth $766K.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 2026968,531$766K0.0%New
Ken Griffin · Citadel AdvisorsQ3 2026751,381$594K0.0%+17%
Jim Simons · Renaissance TechnologiesQ3 2026540,540$428K0.0%+25%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named RANI in the last 120 days.

FiledHolderFormStake
Nov 12, 2026Invus Public Equities, L.P.13G/A8.9%
Nov 12, 2026Invus Public Equities, L.P.13G/A8.9%

Questions about Rani Therapeutics Holdings, Inc. (RANI) stock

Who owns the most RANI stock?

The largest reported owner of Rani Therapeutics Holdings, Inc. (RANI) is Samsara Biocapital, LLC. In total, 66 funds and institutions reported holding RANI at the end of Q2 2026. See the largest owners.

Are RANI insiders buying or selling?

In the last 12 months, RANI insiders reported 2 open-market purchases worth $50K and 1 sale worth $301. The latest trade was on Jul 21, 2026. See every trade.

What is the short interest in RANI?

As of Oct 30, 2026, 8.22M RANI shares were sold short, up 0.8% from the report before. At the average daily volume of 477,910 shares, buying them all back would take about 17.2 trading days (days to cover). See the history.

Which famous investors hold RANI?

3 of the 50 well-known investors we track reported RANI in their latest 13F filing, including Israel Englander, Ken Griffin, Jim Simons. The largest position is worth $766K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.